192 related articles for article (PubMed ID: 33191799)
1. AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence.
McCarthy PM; Clifton GT; Vreeland TJ; Adams AM; O'Shea AE; Peoples GE
Expert Opin Investig Drugs; 2021 Jan; 30(1):5-11. PubMed ID: 33191799
[TBL] [Abstract][Full Text] [Related]
2. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
Mittendorf EA; Ardavanis A; Symanowski J; Murray JL; Shumway NM; Litton JK; Hale DF; Perez SA; Anastasopoulou EA; Pistamaltzian NF; Ponniah S; Baxevanis CN; von Hofe E; Papamichail M; Peoples GE
Ann Oncol; 2016 Jul; 27(7):1241-8. PubMed ID: 27029708
[TBL] [Abstract][Full Text] [Related]
3. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
[TBL] [Abstract][Full Text] [Related]
4. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Brown TA; Mittendorf EA; Hale DF; Myers JW; Peace KM; Jackson DO; Greene JM; Vreeland TJ; Clifton GT; Ardavanis A; Litton JK; Shumway NM; Symanowski J; Murray JL; Ponniah S; Anastasopoulou EA; Pistamaltzian NF; Baxevanis CN; Perez SA; Papamichail M; Peoples GE
Breast Cancer Res Treat; 2020 Jun; 181(2):391-401. PubMed ID: 32323103
[TBL] [Abstract][Full Text] [Related]
5. CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37).
Mittendorf EA; Holmes JP; Murray JL; von Hofe E; Peoples GE
Expert Opin Biol Ther; 2009 Jan; 9(1):71-8. PubMed ID: 19063694
[TBL] [Abstract][Full Text] [Related]
6. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract][Full Text] [Related]
7. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
8. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
[TBL] [Abstract][Full Text] [Related]
9. AE37: a novel T-cell-eliciting vaccine for breast cancer.
Sears AK; Perez SA; Clifton GT; Benavides LC; Gates JD; Clive KS; Holmes JP; Shumway NM; Van Echo DC; Carmichael MG; Ponniah S; Baxevanis CN; Mittendorf EA; Papamichail M; Peoples GE
Expert Opin Biol Ther; 2011 Nov; 11(11):1543-50. PubMed ID: 21895539
[TBL] [Abstract][Full Text] [Related]
10. AE37 HER2-targeted vaccine in the prevention of breast cancer recurrence: A mini narrative review of current evidence.
Olatunji G; Kokori E; Yusuf IA; Akinmoju O; Isarinade T; Komolafe R; Akinoso A; Akinboade A; Osaghae O; Abdulbasit M; Aderinto N
Medicine (Baltimore); 2023 Dec; 102(52):e36793. PubMed ID: 38206732
[TBL] [Abstract][Full Text] [Related]
11. Invariant chain-peptide fusion vaccine using HER-2/neu.
Perez SA; Peoples GE; Papamichail M; Baxevanis CN
Methods Mol Biol; 2014; 1139():321-36. PubMed ID: 24619690
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and antitumor activity of the superlytic λF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice.
Barati N; Razazan A; Nicastro J; Slavcev R; Arab A; Mosaffa F; Nikpoor AR; Badiee A; Jaafari MR; Behravan J
Cancer Lett; 2018 Jun; 424():109-116. PubMed ID: 29580807
[TBL] [Abstract][Full Text] [Related]
13. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide.
Gates JD; Clifton GT; Benavides LC; Sears AK; Carmichael MG; Hueman MT; Holmes JP; Jama YH; Mursal M; Zacharia A; Ciano K; Khoo S; Stojadinovic A; Ponniah S; Peoples GE
Vaccine; 2010 Nov; 28(47):7476-82. PubMed ID: 20858449
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
Benavides LC; Sears AK; Gates JD; Clifton GT; Clive KS; Carmichael MG; Holmes JP; Mittendorf EA; Ponniah S; Peoples GE
Expert Rev Vaccines; 2011 Feb; 10(2):201-10. PubMed ID: 21332269
[TBL] [Abstract][Full Text] [Related]
15. A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.
Anastasopoulou EA; Voutsas IF; Keramitsoglou T; Gouttefangeas C; Kalbacher H; Thanos A; Papamichail M; Perez SA; Baxevanis CN
Cancer Immunol Immunother; 2015 Sep; 64(9):1123-36. PubMed ID: 26026288
[TBL] [Abstract][Full Text] [Related]
16. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial.
Perez SA; Anastasopoulou EA; Tzonis P; Gouttefangeas C; Kalbacher H; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2013 Oct; 62(10):1599-608. PubMed ID: 23934022
[TBL] [Abstract][Full Text] [Related]
17. HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment.
Zhou Y
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6711-6718. PubMed ID: 36692548
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
Norell H; Poschke I; Charo J; Wei WZ; Erskine C; Piechocki MP; Knutson KL; Bergh J; Lidbrink E; Kiessling R
J Transl Med; 2010 Jun; 8():53. PubMed ID: 20529245
[TBL] [Abstract][Full Text] [Related]
19. Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine.
Knutson KL; Block MS; Norton N; Erskine CL; Hobday TJ; Dietz AB; Padley D; Gustafson MP; Puglisi-Knutson D; Mangskau TK; Chumsri S; Dueck AC; Karyampudi L; Wilson G; Degnim AC
Clin Cancer Res; 2020 Mar; 26(5):1045-1053. PubMed ID: 31757875
[TBL] [Abstract][Full Text] [Related]
20. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
